

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boill Healthcare Holdings Limited

保集健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1246)

RESUMPTION OF TRADING

Reference is made to the announcement of Boill Healthcare Holdings Limited (the “**Company**”) dated 2 July 2024 in relation to the trading halt in the shares of the Company (the “**Shares**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from 9:00 a.m. on Tuesday, 2 July 2024 pending the publication of the audited consolidated annual results of the Company and its subsidiaries for the year ended 31 March 2024.

The board of directors of the Company (the “**Board**”) announces that an application has been made by the Company to the Stock Exchange for the resumption of trading in the Shares on the Stock Exchange, and the trading in the Shares on the Stock Exchange was resumed at 1:00 p.m. on Tuesday, 2 July 2024.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Shares.

By order of the Board
Boill Healthcare Holdings Limited
Qiu Dongfang
Executive Director and Chairman

Hong Kong, 2 July 2024

As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Qiu Dongfang and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Ms. Tang Man Yi, Mr. Yi Baxian and Mr. Wang Zhe.